COMMUNIQUÉS West-GlobeNewswire

Beta Bionics to Pre-Announce Topline Fourth Quarter 2025 Financial Results the Week of January 5, 2026
08/12/2025
IRVINE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX) (the “Company”), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to pre [...]
Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
08/12/2025
CLEVELAND, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced the first commercial patient treatment with FDA-approved ZEVASKYN (prademagene zamikeracel), a first-of-its-kind, [...]
BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review
08/12/2025
Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in BX011, its phage program [...]
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
08/12/2025
-- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a [...]
Wave Life Sciences Announces Positive Interim Data from Phase 1 INLIGHT Trial of WVE-007 (INHBE) for Obesity; Single Dose Resulted in Improvement in Body Composition With Fat Loss Similar to GLP-1 at Three Months Without Muscle Loss
08/12/2025
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body [...]
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
08/12/2025
REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12) After 12 weeks off therapy (week [...]
Kraig Biocraft Laboratories Secures Usage Rights to Strategic Government-Owned Mulberry Gardens to Support Major Spider Silk Production Expansion
08/12/2025
ANN ARBOR, Mich., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, today announced that it has been granted usage [...]
Iridex Announces New Thermal Dynamics Study That Strengthens Clinical Foundation and Market Potential of MicroPulse® Technology and Continuous-Wave Laser for Glaucoma Treatment
08/12/2025
MOUNTAIN VIEW, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and accessories for the [...]
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting
08/12/2025
Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension in patients [...]
AskForHelpToday.ca Launches in New Brunswick, Improving Access to Mental Health Care
08/12/2025
TORONTO and FREDERICTON, New Brunswick, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The Ontario Psychological Association (OPA), the College of Psychologists of New Brunswick (CPNB), and Strata Health Solutions are proud to [...]
AskForHelpToday.ca est lancé au Nouveau-Brunswick, améliorant l’accès aux soins en santé mentale
08/12/2025
TORONTO and FREDERICTON, Nouveau-Brunswick, 08 déc. 2025 (GLOBE NEWSWIRE) -- l’Association des Psychologues de l’Ontario (APO), le Collège des psychologues du Nouveau-Brunswick (CPNB) et Strata Santé sont fiers d’ [...]
Virbac : Declaration of the number of shares and voting rights 11/2025
08/12/2025
DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]
Virbac : Déclaration d'actions et de droits de vote 11/2025
08/12/2025
DECLARATION D’ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d’actions composant le capital (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) [...]
Pan Cancer T Secures EUR 10 Million to Advance First-in-Human Trial of Novel TCR-T Cell Therapy for Triple-Negative Breast Cancer
08/12/2025
ROTTERDAM, the Netherlands, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a biotech company pioneering next-generation T cell therapies for solid tumours, today announced a EUR 10 million financing to advance its [...]
Geneva College of Longevity Science and DrVibe.ai Launch the GCLS AI Academy for Longevity Sciences
08/12/2025
First Multi-Agent AI System for Higher Longevity Education to Offer Free Courses and Pave the Way for a Master’s Degree in AI in Healthcare New Website: https://gcls.ai GENEVA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- The [...]
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia
08/12/2025
Amphista Therapeutics presents new preclinical data showing the potential of its BRD9 Targeted Glue™, AMX-883, to transform the treatment paradigm for acute myeloid leukaemia AMX-883-induced BRD9 degradation is [...]
Pharming Group to participate in Oppenheimer Movers in Rare Disease Summit
08/12/2025
Leiden, the Netherlands, December 8, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced its participation in the Oppenheimer Movers in Rare Disease Summit on December 11, [...]
EpiEndo Pharmaceutical's ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients
08/12/2025
ERJ Open Research article reports first clinical trial of glasmacinal (EP395) in COPD patients Glasmacinal, a novel macrolide, was well tolerated and reduced neutrophilic inflammation in COPD patients. Glasmacinal had [...]
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL
08/12/2025
FIRST PATIENT DOSED IN CITRYLL’S PHASE IIA HIDRADENITIS SUPPURATIVA TRIAL Multi-center, randomized study designed to assess the efficacy, safety, and tolerability of CIT-013 in patients with hidradenitis suppurativa [...]

Pages